Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Author(s)

Alves, Aline de Cristo Soares ^[1] ; Bruinsmann, Franciele Aline ^[1] ; Guterres, Silvia Staniscuaski ^[1] ; Pohlmann, Adriana Raffin ^[1]

Affiliation

^[1] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Farmaceut, BR-90610000 Porto Alegre, RS - Brazil

• Document type: Review article
• Source: Molecules; v. 26, n. 14 JUL 2021.
• Web of Science Citations: 0

Abstract

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance. (AU)

• FAPESP's process: 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach
• Grantee: Maria Vitória Lopes Badra Bentley
• Support Opportunities: Research Projects - Thematic Grants